Testosterone declines approximately 1–2% per year after age 30, and by age 70, most men have levels 40–50% below their peak. The European Male Ageing Study found that 20–30% of men over 50 fall below the clinical cutoff of 300 ng/dL. This guide covers TRT mechanisms, dosing protocols, monitoring markers, and safety data from published clinical trials.
Testosterone is the primary androgen in men, produced mainly by Leydig cells in the testes under hypothalamic-pituitary-gonadal (HPG) axis control. GnRH from the hypothalamus stimulates LH release from the pituitary, which signals the testes to produce testosterone. This system operates via negative feedback — exogenous testosterone suppresses GnRH and LH, which is why TRT causes testicular atrophy and fertility suppression.
Once in circulation, testosterone exerts effects through multiple pathways. Understanding these is critical for grasping both the benefits and side effects of TRT.
Testosterone binds the intracellular androgen receptor (AR), which translocates to the nucleus and acts as a transcription factor — activating genes for muscle protein synthesis, bone formation, and red blood cell production. AR density varies by tissue, explaining why effects have different timelines.
The enzyme 5α-reductase converts testosterone to dihydrotestosterone (DHT), a more potent androgen with 3–10× greater AR affinity. DHT drives prostate growth, body/facial hair, and scalp hair loss. It cannot be aromatized to estrogen, making it purely androgenic.
Aromatase enzyme (CYP19A1), concentrated in adipose tissue, converts testosterone to estradiol (E2). This estrogen is essential for bone density, joint health, cognitive function, and cardiovascular protection in men. Excessive aromatization in obese men can cause gynecomastia and further suppress the HPG axis.
Testosterone also acts through rapid, non-genomic pathways independent of nuclear AR signaling — including vasodilation, calcium flux in muscle cells, and rapid mood/energy effects. These membrane-initiated actions explain why some TRT effects (energy, mood) appear within days.
Serum total testosterone declines approximately 1–2% per year after age 30, based on longitudinal data from the Baltimore Longitudinal Study of Aging and the Massachusetts Male Aging Study. By age 70, many men have total testosterone levels 40–50% lower than their peak. The European Male Ageing Study found that 20–30% of men over 50 have total testosterone below the commonly used cutoff of 300 ng/dL (10.4 nmol/L).
⚡ Important: These are population averages. Individual decline rates vary substantially based on body composition, metabolic health, sleep, stress, and genetics. Obesity alone can lower testosterone by 30–40% independent of age.
The bars below show approximate average total testosterone by decade, derived from cross-sectional population studies. Reference range for healthy young men: 300–1,000 ng/dL.
All forms below are FDA-approved for the treatment of male hypogonadism (total testosterone consistently <300 ng/dL with symptoms). The goal of therapy is to restore levels to the mid-normal physiological range of 500–800 ng/dL, per Endocrine Society guidelines.
Intramuscular or subcutaneous injection. Oil-based depot formulation with a half-life of approximately 8 days.
Nearly identical pharmacokinetics to cypionate. Slight difference in ester weight; clinically interchangeable.
Transdermal gel applied daily to shoulders, upper arms, or abdomen. Provides steady-state levels without injection peaks and troughs.
Transdermal patch applied to trunk, upper arm, or thigh. Delivers testosterone in a circadian pattern mimicking natural secretion.
Subcutaneous implants inserted in the hip/gluteal area under local anesthesia. Longest-acting formulation available.
Intranasal gel applied to the inner nostril. Avoids transference risk to partners/children that gels carry.
💡 Split dosing: Many clinicians now prescribe twice-weekly injections (e.g., 80 mg Monday + 80 mg Thursday) to reduce peak-trough variation and minimize side effects like estradiol spikes and hematocrit elevation. Subcutaneous injection using insulin needles (29–30g) is increasingly preferred over intramuscular for comfort and self-administration.
The onset and time-to-maximum of TRT effects vary significantly by target tissue and outcome, as documented by Saad et al. in their systematic review of replacement therapy studies. Effects are mediated by both genomic (slower, gene transcription) and non-genomic (rapid, membrane signaling) pathways.
Per Endocrine Society Clinical Practice Guidelines, baseline labs should be drawn before initiating TRT, with follow-up at 3, 6, and 12 months, then annually. Morning fasting blood draw preferred. Target total testosterone: 500–800 ng/dL at trough (for injections, draw just before next dose).
The following incidence data come from the TRAVERSE trial (N=5,246, mean follow-up 33 months), the TRT Trials, and meta-analyses. Erythrocytosis (elevated hematocrit) remains the most common dose-related adverse effect. The TRAVERSE trial conclusively demonstrated no increased risk of major adverse cardiovascular events (MACE) compared to placebo.
⚠️ Fertility warning: Exogenous testosterone suppresses the HPG axis, reducing intratesticular testosterone to near zero. This causes spermatogenic arrest in approximately 90% of men. TRT is NOT a form of reliable contraception, but men desiring fertility should use alternatives (clomiphene citrate, hCG, or enclomiphene) or use hCG concurrently to maintain testicular function.
For men with borderline testosterone (250–400 ng/dL), lifestyle optimization should be attempted first. The following comparison is based on published intervention studies.
💡 Weight loss is the single most effective natural intervention. Camacho et al. (EMAS, PMID: 23161753) showed that a 15% reduction in BMI increased total testosterone by an average of 2.9 nmol/L (~84 ng/dL). Conversely, a 15% weight gain decreased it by 2.4 nmol/L (~69 ng/dL). Address obesity before considering TRT.
The following landmark studies form the foundation of modern TRT clinical practice.
Lincoff AM, et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." N Engl J Med 2023;389:107-117. N=5,246 hypogonadal men with CV risk. Mean follow-up 33 months. TRT was noninferior to placebo for MACE.
PubMed: 37326322 →Snyder PJ, et al. "Effects of Testosterone Treatment in Older Men." N Engl J Med 2016;374:611-624. N=790 men ≥65 with T<275. Improved sexual function, physical activity, vitality, and bone density at 12 months.
PubMed: 26951529 →Saad F, et al. "Onset of effects of testosterone treatment and time span until maximum effects are achieved." Eur J Endocrinol 2011;165:675-685. Comprehensive review of onset and maximal effects by system.
PubMed: 21849027 →Harman SM, et al. "Longitudinal effects of aging on serum total and free testosterone in healthy men." J Clin Endocrinol Metab 2001;86:724-731. Established the ~1–2% annual decline rate in 890 men followed longitudinally.
PubMed: 11502781 →Feldman HA, et al. "Age trends in the level of serum testosterone and other hormones in middle-aged men." J Clin Endocrinol Metab 2002;87:589-598. Population-based study confirming age-related decline in 1,709 men.
PubMed: 11836290 →Wu FC, et al. "Identification of late-onset hypogonadism in middle-aged and elderly men." N Engl J Med 2010;363:123-135. Defined symptom-based diagnostic criteria for late-onset hypogonadism. N=3,369.
PubMed: 20554979 →Bhasin S, et al. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab 2018;103:1715-1744. Current standard of care recommendations.
PubMed: 29562364 →Camacho EM, et al. "Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors." Eur J Endocrinol 2013;168:445-455.
PubMed: 23161753 →Products relevant to testosterone optimization and TRT administration.
Affiliate links help support HighPeptides at no extra cost to you.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Testosterone is primarily synthesized overnight during sleep. A single night of sleep deprivation can drop testosterone levels by 10–15%. Beyond low T, TRT itself carries two sleep-specific risks you need to monitor: sleep apnea worsening (testosterone increases upper airway muscle relaxation) and nocturia (the need to urinate at night, fragmenting sleep). Screen for both at baseline.
The ROI math is simple: if you're sleeping 5–6 hours, you're suppressing overnight testosterone synthesis regardless of what you're injecting. Optimizing sleep isn't optional for TRT users — it's part of the protocol.
→ Sleep Optimization for TRT & Peptide Users⚕️ Medical Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Testosterone replacement therapy is an FDA-approved prescription medication for diagnosed hypogonadism. Never self-prescribe testosterone. Always consult with a qualified healthcare provider — ideally an endocrinologist or urologist — before starting, adjusting, or discontinuing any hormone therapy. All data sourced from published peer-reviewed research with PubMed citations provided.